{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:40:36Z","timestamp":1783212036376,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.pnpbp.2008.04.018","type":"journal-article","created":{"date-parts":[[2008,5,8]],"date-time":"2008-05-08T13:31:05Z","timestamp":1210253465000},"page":"1453-1458","source":"Crossref","is-referenced-by-count":44,"title":["Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model"],"prefix":"10.1016","volume":"32","author":[{"given":"Sheila","family":"Botts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Muscatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myladis","family":"Cogollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2008.04.018_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.jcp.0000227353.46450.52","article-title":"Valproate lowers plasma concentrations of olanzapine","volume":"26","author":"Bergemann","year":"2006","journal-title":"J Clin Psychopharm"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4088\/JCP.v65n0817","article-title":"Variables associated with high olanzapine dosing in a state hospital","volume":"65","author":"Botts","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib3","series-title":"Applied mixed models in medicine","author":"Brown","year":"2001"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.ftd.0000211800.66569.c9","article-title":"Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection","volume":"28","author":"D'Arrigo","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1461145703003249","article-title":"Glucuronidation enzymes, genes and psychiatry","volume":"6","author":"de Leon","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ps.55.2.125","article-title":"Psychopharmacology. Atypical antipsychotic dosing: the effect of co-medication with anticonvulsants","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ps.55.5.491","article-title":"Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics","volume":"46","author":"de Leon","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2007.01.015","article-title":"A clinical study of the association of antipsychotics with hyperlipidemia","volume":"92","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib10","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/sim.2636","article-title":"Individualizing drug dosage by using a random intercept linear model","volume":"26","author":"Diaz","year":"2007","journal-title":"Statist Med"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib12","series-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2004"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","article-title":"Therapeutic monitoring of new antipsychotic drugs","volume":"26","author":"Hiemke","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1592\/phco.26.5.627","article-title":"Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers","volume":"26","author":"Jann","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib16","first-page":"512","article-title":"Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes","volume":"24","author":"Linnet","year":"2002","journal-title":"Hum Psyhcopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00007691-200208000-00009","article-title":"Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine co-medication","volume":"24","author":"Linnet","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib18","series-title":"SAS for mixed models","author":"Littell","year":"2006"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.wnf.0000240955.49315.65","article-title":"Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders","volume":"30","author":"Migliardi","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1528-1167.2005.71104.x","article-title":"Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine","volume":"46","author":"Muscatello","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The relationship between the response of clinical symptoms and plasma olanzapine concentration, Based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)","volume":"30","author":"Nozawa","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2125.2006.02598.x","article-title":"Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Tox"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.ftd.0000246763.59506.b0","article-title":"Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder","volume":"28","author":"Spina","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pnpbp.2008.04.018_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacol Res"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584608001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584608001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:55:42Z","timestamp":1546041342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584608001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0278584608001346"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2008.04.018","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}